| CAS No.: | 910463-68-2 |
|---|---|
| Variety: | Powder |
| Feature: | Eco-Friendly |
| Usage: | Organic Chemical Material |
| Status: | Solid State |
| State: | Solid |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.
Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.
Product Specification
| Items | Specifications |
| Product Name | Tirzepatide |
| Other Name | LY3298176 |
| CAS | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Appearance | White power |
| Molar Mass | 4813.45 |
Appearance: Powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
Tirzepatide (LY3298176) is a dual glucose-dependent insulotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
This medication is designed to improve glycemic control in people with type 2 diabetes by targeting both the GIP and GLP-1 receptors. By stimulating these receptors, tirzepatide can increase insul secretion and decrease glucagon secretion in a glucose-dependent manner, helping to lower blood sugar levels.
Clinical trials have shown promising results in terms of reducing HbA1c levels and body weight in individuals with type 2 diabetes. Tirzepatide is being studied in various dosages and formulations to determine its effectiveness, safety, and potential benefits for people with diabetes
NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.
Shipping & Storage
Shipping: Deliver to worldwide by Fedex / DHL(Free shipping for orders over a certain amount)
Provide with the goods: quality analysis report (COA,MS,HPLC)
Storage condition: 2-8 ° C
Q: How to start orders or make payments?
A:You can send our your Purchase order(if your company has), or just send a simple confirmation by email or by Trade Manager, and we will send you Proforma Invoice with our bank details for your confirmation, then you can make payment accordingly.
Suppliers with verified business licenses
){kind=link}
){kind=link}